Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

About this update from Outlook Therapeutics, Inc.

[{"type":"image","alt":"Outlook Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Outlook Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":80,"url":"https://media.zenfs.com/en/globenewswire.com/036f630f46be050c02b981afef3ca9e4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qNsjgbA2tq9jniYix8cXEg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/036f630f46be050c02b981afef3ca9e4","width":300,"height":80}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK)","length":158,"tagName":"p"}]},{"val":[{"type":"text","content":"2.8 million injections of repackaged off-label bevacizumab in Europe each year1","length":79,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":237,"olType":false},{"type":"text","content":"ISELIN, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that LYTENAVA™ (bevacizumab gamma) is now commercially available in Germany and the UK for the treatment of wet age-related macular degeneration (wet AMD). LYTENAVA™ (bevacizumab gamma) is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in adults in the European Union and UK.","length":555,"tagName":"p"},{"type":"text","content":"“We are excited to have launched LYTENAVA™ (bevacizumab gamma) for patients with wet AMD in Germany and the UK. I would like to extend sincere gratitude to the Outlook team and our partners for their commitment and dedication that helped to get us to this major milestone. Going forward, we remain laser focused on ensuring success in Germany and the UK as well as preparing for additional launches across the region later this year and throughout 2026,” commented Jedd Comiskey, Senior Vice President, Head of Europe at Outlook Therapeutics.","length":542,"tagName":"p"},{"type":"text","content":"Off-label repackaged bevacizumab is one of the most frequently used first-line anti-VEGF treatments in Europe (approximately 2.8 million injections annually) and ...

More updates from Outlook Therapeutics, Inc.